Nov 18 (Reuters) - Pfizer Inc and its German partner BioNTech SE said on Friday their Omicron-tailored shot produced higher virus-neutralizing antibodies in older adults against the emerging subvariant BQ.1.1 than its original vaccine.

Antibody levels against the BQ.1.1 variant rose nearly 9 times in older adults who received the Omicron shot compared to a 2-fold increase in participants with the original shot, according to data posted on the online archive bioRxiv. (Reporting by Bhanvi Satija in Bengaluru; Editing by Krishna Chandra Eluri)